HPMA copolymer-anticancer drug conjugates: Design, activity, and mechanism of action

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 50, Issue 1, 2000, Pages 61-81

  Kopeček, Jindřich ^a,b   Kopečková, Pavla ^a,b   Minko, Tamara ^a   Lu, Zheng Rong ^a  

^a UNIVERSITY OF UTAH   (United States)

^b Department of Electrical and Computer Engineering   (United States)

Author keywords

Anticancer drugs; Cancer treatment; HPMA copolymer; HPMA copolymer based prodrugs; Macromolecular therapeutics; Multidrug resistance

Indexed keywords

ANTINEOPLASTIC AGENT; COPOLYMER; DOXORUBICIN; DRUG CARRIER; N (2 HYDROXYPROPYL)METHACRYLAMIDE; PRODRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER; CLINICAL TRIAL; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; MACROMOLECULE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; POLYMERIZATION; REVIEW; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOCOMPATIBLE MATERIALS; DRUG DESIGN; GENE THERAPY; HUMANS; METHACRYLATES; NEOPLASMS;

EID: 0041181628     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(00)00075-8     Document Type: Review

References (178)

1. Ehrlich P. Studies in Immunity. 1906;Plenum Press, New York.
2. De Duve C., De Barsy T., Poole B., Trouet A., Tulkens P., van Hoof F. Lysosomotropic agents. Biochem. Pharmacol. 23:1974;2495-2531.
3. Jatzkewitz H. Peptamin (glycyl-L-leucyl-mescaline) bound to blood plasma expander (polyvinylpyrrolidone) as a new depot form of a biologically active primary amine (mescaline). Z. Naturforsch. 10b:1955;27-31.
4. Panarin E.F., Ushakov S.N. Synthesis of polymer salts and amidopenicillines (in Russian). Khim. Pharm. Zhur. 2:1968;28-31.
5. Mathé G., Loc T.B., Bernard J. Effect sur la leucémie L1210 de la souris d'une combinaison par diazotation d'A méthoptérine et de γ-globulines de hamsters porteurs de cette leucémie par hétérogreffe. Compte-rendus del'Académie des Sciences. 3:1958;1626-1628.
6. Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci. Polym. Symp. 51:1975;135-153.
7. Wichterle O., Lím D. Hydrophilic gels for biological use. Nature. 185:1960;117-118.
8. O. Wichterle, Hydrogel contact lenses, US Patent 3,496,254 (1964).
9. Šprincl L., Vacík J., Kopeček J., Lím D. Biological tolerance of poly(N-substituted methacrylamides). J. Biomed. Mater. Res. 5:1971;197-205.
10. Šprincl L., Kopeček J., Lím D. Effect of porosity of heterogeneous poly(glycol monomethacrylate) gels on the healing-in of test implants. J. Biomed. Mater. Res. 5:1971;447-458.
11. Kopeček J., Šprincl L., Bažilová H., Vacík J. Biological tolerance of poly(N-substituted acrylamides). J. Biomed. Mater. Res. 7:1973;111-121.
12. Šprincl L., Kopeček J., Lím D. Effect of the structure of poly(glycol monomethacrylate) gels on the calcification of implants. Calcif. Tissue Res. 13:1973;63-72.
13. Kopeček J., Šprincl L. Relationship between the structure and biocompatibility of hydrophilic gels. Polym. Med. (Wroclaw). 4:1974;109-117.
14. Kopeček J., Šprincl L., Lím D. New types of synthetic infusion solutions. I. Investigation of the effect of solutions of some hydrophilic polymers on blood. J. Biomed. Mater. Res. 7:1973;179-191.
15. Voldřich Z., Tománek Z., Vacík J., Kopeček J. Long-term experience with the poly(glycol monomethacrylate) gel in plastic operations of the nose. J. Biomed. Mater. Res. 9:1975;675-685.
16. Kopeček J. Soluble biomedical polymers. Polym. Med. (Wroclaw). 7:1977;191-221.
17. Kopeček J. Soluble polymers in medicine. Williams D.F. Systemic Aspects of Biocompatibility. II:1981;159-180 CRC Press, Boca Raton, FL.
18. Kopeček J., Bažilová H. Poly[N-(2-hydroxypropyl)methacrylamide]. I. Radical polymerization and copolymerization. Eur. Polym. J. 9:1973;7-14.
19. Bohdanecký M., Bažilová H., Kopeček J. Poly[N-(2-hydroxypropyl)methacrylamide]. II. Hydrodynamic properties of diluted polymer solutions. Eur. Polym. J. 10:1974;405-410.
20. Drobník J., Kopeček J., Labský J., Rejmanová P., Exner J., Saudek V., Kálal J. Enzymatic cleavage of side-chains of synthetic water-soluble polymers. Makromol. Chem. 177:1976;2833-2848.
21. Kopeček J., Cífková I., Rejmanová P., Strohalm J., Obereigner B., Ulbrich K. Polymers containing enzymatically degradable bonds. 4. Preliminary experiments in vivo. Makromol. Chem. 182:1981;2941-2949.
22. Rejmanová P., Labský J., Kopeček J. Aminolyses of monomeric and polymeric p-nitrophenyl esters of methacryloylated amino acids. Makromol. Chem. 178:1977;2159-2168.
23. Kopeček J. Reactive copolymers of N-(2-hydroxypropyl)methacrylamide with N-methacryloylated derivatives of L-leucine and L-phenylalanine. I. Preparation, characterization and reaction with diamines. Makromol. Chem. 178:1977;2169-2183.
24. Kopeček J., Rejmanová P. Reactive copolymers of N-(2-hydroxypropyl)methacrylamide with N-methacryloylated derivatives of L-leucine and L-phenylalanine. II. Reaction with the polymeric amine and stability of crosslinks towards chymotrypsin in vitro. J. Polym. Sci. Polym. Symp. 66:1979;15-32.
25. Chytrý V., Vrána A., Kopeček J. Synthesis and activity of a polymer which contains insulin covalently bound on a copolymer of N-(2-hydroxypropyl)methacrylamide and N-methacryloylglycylglycine 4-nitrophenyl ester. Makromol. Chem. 179:1978;329-336.
26. Solovskij M.V., Ulbrich K., Kopeček J. Synthesis of N-(2-hydroxypropyl)methacrylamide copolymers with antimicrobial activity. Biomaterials. 4:1983;44-48.
27. Obereigner B., Burešová M., Vrána A., Kopeček J. Preparation of polymerizable derivatives of N-(4-aminobenzenesulfonyl)-N′-butylurea. J. Polym. Sci. Polym. Symp. 66:1979;41-52.
28. Lloyd J.B. Soluble polymers as targetable drug carriers. Johnson P., Lloyd-Jones J.G. Drug Delivery Systems Fundamentals and Techniques. 1987;95-105 Ellis Harwood, Chichester.
29. Duncan R., Cable H.C., Rejmanová P., Kopeček J., Lloyd J.B. Tyrosinamide residues enhance pinocytic capture of N-(2-hydroxypropyl)methacrylamide copolymers. Biochim. Biophys. Acta. 799:1984;1-8.
30. McCormick L.A., Seymour L.C.W., Duncan R., Kopeček J. Interaction of a cationic N-(2-hydroxypropyl)methacrylamide copolymer with rat visceral yolk sac cultured in vitro and rat liver in vivo. J. Bioact. Comp. Polym. 1:1986;4-19.
31. Duncan R., Kopeček J., Rejmanová P., Lloyd J.B. Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues. Biochim. Biophys. Acta. 755:1983;518-521.
32. Říhová B., Kopeček J. Biological properties of targetable poly[N-(2-hydroxypropyl)methacrylamide]-antibody conjugates. J. Control. Release. 2:1985;289-310.
33. Kopeček J. Biodegradation of polymers for biomedical use. Benoit H., Rempp P. IUPAC Macromolecules. 1982;305-320 Pergamon Press, Oxford.
34. Kopeček J. Controlled biodegradability of polymers - a key to drug delivery systems. Biomaterials. 5:1984;19-25.
35. J. Kopeček, P. Rejmanová, J. Strohalm, K. Ulbrich, B. Říhová, V. Chytrý, J.B. Lloyd, R. Duncan, Synthetic polymeric drugs, US Patent 5,037,883 (1991).
36. Putnam D., Kopeček J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122:1995;55-123.
37. Foster S., Lloyd J.B. Solute transport across the mammalian lysosome membrane. Biochim. Biophys. Acta. 947:1988;465-491.
38. Shen W.-C., Ryser H.J.P. Cis-aconityl spacer between daunomycin and macromolecular carriers: a model of pH sensitive linkage releasing drug from a lysosomotropic conjugate. Biochem. Biophys. Res. Commun. 102:1981;1048-1054.
39. Choi W.-M., Kopečková P., Minko T., Kopeček J. Synthesis of HPMA copolymer containing adriamycin bound via an acid-labile spacer and its activity toward human ovarian carcinoma cells. J. Bioact. Comp. Polym. 14:1999;447-556.
40. Kopeček J., Rejmanová P. Enzymatically degradable bonds in synthetic polymers. Bruck S.D. Controlled Drug Delivery. I:1983;81-124 CRC Press, Boca Raton, FL.
41. Kopeček J., Rejmanová P., Chytrý V. Polymers containing enzymatically degradable bonds. 1. Chymotrypsin catalyzed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side-chains of copolymers of N-(2-hydroxypropyl)methacrylamide. Makromol. Chem. 182:1981;799-809.
42. Ulbrich K., Strohalm J., Kopeček J. Polymers containing enzymatically degradable bonds. 3. Poly[N-(2-hydroxypropyl)methacrylamide] chains connected by oligopeptide sequences cleavable by trypsin. Makromol. Chem. 182:1981;1917-1928.
43. Ulbrich K., Zacharieva E.I., Obereigner B., Kopeček J. Polymers containing enzymatically degradable bonds. 5. Hydrophilic polymers degradable by papain. Biomaterials. 1:1980;199-204.
44. Rejmanová P., Kopeček J., Duncan R., Lloyd J.B. Stability in rat plasma and serum of lysosomally degradable oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers. Biomaterials. 6:1985;45-48.
45. Duncan R., Cable H.C., Lloyd J.B., Rejmanová P., Kopeček J. Polymers containing enzymatically degradable bonds. 7. Design of oligopeptide side-chains in poly[N-(2-hydroxypropyl)methacrylamide] copolymers to promote efficient degradation by lysosomal enzymes. Makromol. Chem. 184:1983;1997-2008.
46. Rejmanová P., Pohl J., Baudyš M., Kostka V., Kopeček J. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 184:1983;2009-2020.
47. Putnam D., Shiah J.-G., Kopeček J. Intracellularly biorecognizable derivatives of 5-fluorouracil: implications of targetable delivery in the human condition. Biochem. Pharmacol. 52:1996;957-962.
48. Rathi R.C., Kopečková P., Říhová B., Kopeček J. N-(2-Hydroxypropyl)methacrylamide copolymers containing pendent saccharide moieties. Synthesis and bioadhesive properties. J. Polym. Sci. Part A: Polym. Chem. 29:1991;1895-1991.
49. Chytrý V., Letourneur D., Vrána A., Jozefonvicz J. Insulin bound to chiral polymer with N-acetyl-D-glucosaminyl units. Lack of mitogenic activity on rat aorta smooth muscle cell proliferation. J. Controll Release. 50:1998;197-203.
50. Říhová B., Kopečková P., Strohalm J., Rossmann P., Větvička V., Kopeček J. Antibody directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugates to HPMA copolymers and targeting antibody. Clin. Immunol. Immunopathol. 46:1988;100-114.
51. Omelyanenko V., Kopečková P., Gentry C., Shiah J.-G., Kopeček J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 1. Influence of the method of synthesis on the binding affinity to OVCAR-3 ovarian carcinoma cells in vitro. J. Drug Targeting. 3:1996;357-373.
52. Lu Z.-R., Kopečková P., Kopeček J. Polymerizable Fab′ antibody fragments for targeting of anticancer drugs. Nat. Biotechnol. 17:1999;1101-1104.
53. Omelyanenko V., Gentry C., Kopečková P., Kopeček J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 2. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer. 75:1998;600-608.
54. Říhová B., Říha I. Immunological problems of polymer-bound drugs. CRC Crit. Rev. Therapeut. Drug Carrier Syst. 1:1984;311-374.
55. Šprincl L., Exner J., Štěrba O., Kopeček J. New types of synthetic infusion solutions. III. Elimination and retention of poly[N-(2-hydroxypropyl)methacrylamide] in a test organism. J. Biomed. Mater. Res. 10:1976;953-963.
56. Korčáková L., Paluska E., Hašková V., Kopeček J. A simple test for immunogenicity of colloidal infusion solutions - the draining lymph node activation. Z. Immun. Forsch. 151:1976;219-223.
57. Paluska E., Činátl J., Korčáková L., Štěrba O., Kopeček J., Hrubá A., Nezvalová J., Staněk R. Immunosuppressive effect of a synthetic polymer - poly[N-(2-hydroxypropyl)methacrylamide] (Duxon). Folia Biol. 26:1980;304-311.
58. Činátl J., Štěrba O., Paluska E., Polednová V., Kopeček J. New types of synthetic infusion solutions. the effects of duxon on the cell proliferation in vitro. Čs. Farmacie. 29:1980;134-138.
59. Paluska E., Hrubá A., Štěrba O., Kopeček J. Effect of a synthetic poly[n-(2-hydroxypropyl)methacrylamide] (Duxon) on haemopoiesis and graft versus host reaction. Folia Biol. 32:1986;91-102.
60. Říhová B., Ulbrich K., Kopeček J., Mančal P. Immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers - potential hapten or drug carriers. Folia Microbiol. 28:1983;217-227.
61. Říhová B., Kopeček J., Ulbrich K., Pospíšil J., Mančal P. Effect of the chemical structure of N-(2-hydroxypropyl)methacrylamide copolymers on their ability to induce antibody formation in inbred strains of mice. Biomaterials. 5:1984;143-148.
62. Říhová R., Kopeček J., Ulbrich K., Chytrý V. Immunogenicity of N-(2-hydroxypropyl)methacrylamide copolymers. Makromol. Chem. 9:(Suppl.):1985;13-24.
63. Šimečková J., Plocová D., Říhová B., Kopeček J. Activity of complement in the presence of N-(2-hydroxypropyl)methacrylamide copolymers. J. Bioact. Comp. Polym. 1:1986;20-31.
64. Flanagan P.A., Duncan R., Říhová B., Šubr V., Kopeček J. Immunogenicity of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates measured in A/J and B10 mice. J. Bioact. Comp. Polym. 5:1990;151-166.
65. Říhová B., Bilej M., Větvička V., Ulbrich K., Strohalm J., Duncan R., Kopeček J. Biocompatibility of N-(2-hydroxypropyl)methacrylamide copolymers containing adriamycin. Biomaterials. 10:1989;335-342.
66. Yeung T.K., Hopewell J.W., Simmonds R.H., Seymour L.W., Duncan R., Bellini O., Grandi M., Spreafico F., Strohalm J., Ulbrich K. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: an experimental study in the rat. Cancer Chemother. Pharmacol. 29:1991;105-111.
67. Duncan R., Seymour L.W., O'Hare K.B., Flanagan P.A., Wedge S., Hume I.C., Ulbrich K., Strohalm J., Šubr V., Spreafico F., Grandi M., Ripamonti M., Farao M., Suarato A. Preclinical evaluation of polymer-bound doxorubicin. J. Control. Release. 19:1992;331-346.
68. Duncan R., Coatsworth J.K., Burtles S. Preclinical toxicology of a novel polymeric antitumor agent: HPMA copolymer-doxorubicin (PK1). Hum. Exp. Toxicol. 17:1998;93-104.
69. Seymour L.W., Duncan R., Strohalm J., Kopeček J. Effect of molecular weight of N-(2-hydroxypropyl)methacrylamide copolymers on body distribution and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J. Biomed. Mater. Res. 21:1987;1341-1358.
70. Crepon B., Jozefonvicz J., Chytrý V., Říhová B., Kopeček J. Enzymatic degradation and immunogenic properties of derivatized dextrans. Biomaterials. 12:1991;550-554.
71. Chiu H.-C., Kopečková P., Deshmane S.S., Kopeček J. Lysosomal degradation of poly(α-amino acids). J. Biomed. Mater. Res. 34:1997;381-392.
72. Chiu H.-C., Koňák Č., Kopečková P., Kopeček J. Enzymatic degradation of poly(ethylene glycol) modified dextrans. J. Bioact. Comp. Polym. 9:1994;388-410.
73. Krinick N.L., Kopeček J. Soluble polymers as targetable drug carriers. Juliano R.L. Targeted Drug Delivery. Handbook of Experimental Pharmacology. Vol. 100:1991;105-179 Springer, Berlin.
74. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer therapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46:1986;6387-6392.
75. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., Maeda H. Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89:1998;307-314.
76. Jain R.K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl. Cancer Inst. 81:1989;570-576.
77. Minko T., Kopečková P., Kopeček J. Efficacy of chemotherapeutic action of HPMA copolymer-bound doxorubicin in a solid tumor model of ovarian carcinoma. Int. J. Cancer. 86:2000;108-117.
78. Cassidy J., Duncan R., Morrison G.J., Strohalm J., Plocová D., Kopeček J., Kaye S.B. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumor model. Biochem. Pharmacol. 38:1989;875-879.
79. 6 and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts. J. Control. Release. 61:1999;145-157.
80. Maeda H., Seymour L.M., Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3:1992;351-362.
81. Yamaoka T., Tabata Y., Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83:1994;601-606.
82. Takakura Y., Fujita T., Hashida M., Sezaki H. Disposition of macromolecules in tumor-bearing mice. Pharm. Res. 7:1990;339-346.
83. Tabata Y., Kawai T., Murakami Y., Ikada Y. Electric charge influence of dextran derivatives on their tumor accumulation after intravenous injection. Drug Deliv. 4:1997;213-221.
84. Steyger P.S., Baban D.F., Brereton M., Ulbrich K., Seymour L.W. Intratumoural distribution as a determinant of tumor responsiveness to therapy using polymer-based macromolecular prodrugs. J. Control. Release. 39:1996;35-46.
85. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. USA. 95:1998;4607-4612.
86. Marecos E., Weissleder R., Bogdanov A. Jr. Antibody-mediated versus nontargeted delivery in a human small cell lung carcinoma model. Bioconjugate Chem. 9:1998;184-191.
87. Cartlidge S.A., Duncan R., Lloyd J.B., Rejmanová P., Kopeček J. Soluble, crosslinked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 1. Pinocytosis by rat visceral yolk sacs and rat intestine cultured in vitro. Effect of molecular weight on uptake and intracellular degradation. J. Control. Release. 3:1986;55-66.
88. Cartlidge S.A., Duncan R., Lloyd J.B., Kopečková-Rejmanová P., Kopeček J. Soluble, crosslinked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 3. Targeting by incorporation of galactosamine residues. Effect of route of administration. J. Control. Release. 4:1987;265-278.
89. Cartlidge S.A., Duncan R., Lloyd J.B., Kopečková-Rejmanová P., Kopeček J. Soluble, crosslinked N-(2-hydroxypropyl)methacrylamide copolymers as potential drug carriers. 2. Effect of molecular weight on blood clearance and body distribution in the rat after intraveneous administration. Distribution of unfractionated copolymer after intraperitoneal, subcutaneous or oral administration. J. Control. Release. 4:1987;253-264.
90. Dvořák M., Kopečková P., Kopeček J. Novel synthesis of long-circulating HPMA copolymer-adriamycin conjugates. Proc. Int. Symp. Control. Release Bioact. Mater. 25:1998;884-885.
91. Dvořák M., Kopečková P., Kopeček J. High-molecular weight HPMA copolymer-adriamycin conjugates. J. Control. Release. 60:1999;321-332.
92. Shiah J.-G., Dvořák M., Sun Y., Peterson C.M., Kopečková P., Kopeček J. Long-circulating HPMA copolymer-adriamycin conjugates, 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA. AAPS Pharm. Sci. 1:1999;S432.
93. Shiah J.-G., Dvořák M., Kopečková P., Sun Y., Peterson C.M., Kopeček J. Therapeutic efficacy of long-circulating HPMA copolymer-doxorubicin conjugates. Eur. J. Cancer. 2000;. submitted.
94. Minko T., Kopečková P., Pozharov V., Kopeček J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release. 54:1998;223-233.
95. Minko T., Kopečková P., Kopeček J. Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J. Control. Release. 59:1999;133-148.
96. Kunath K., Kopečková P., Minko T., Kopeček J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. 3. The effect of free and polymer-bound adriamycin on the expression of some genes in the OVCAR-3 human ovarian carcinoma cell line. Eur. J. Pharm. Biopharm. 49:2000;11-15.
97. Minko T., Kopečková P., Kopeček J. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm. Res. 16:1999;986-996.
98. Říhová B. Antibody-targeted polymer-bound drugs. Folia Microbiol. 40:1995;367-384.
99. Mammen M., Choi S.-K., Whitesides G.M. Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors. Angew. Chem. Int. Ed. 37:1998;2754-2794.
100. Duncan R., Seymour L.C.W., Scarlett L., Lloyd J.B., Rejmanová P., Kopeček J. Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendent galactosamine residues after intravenous administration to rats. Biochim. Biophys. Acta. 880:1986;62-71.
101. Sigal G.B., Mammen M., Dahman G., Whitesides G.M. Polyacrylamides bearing pendant sialoside groups strongly inhibit agglutination of erythrocytes by influenza virus: the strong inhibition reflects enhanced binding through cooperative polyvalent interactions. J. Am. Chem. Soc. 118:1996;3789-3800.
102. Rathi R.C., Kopečková P., Kopeček J. Biorecognition of sugar containing N-(2-hydroxypropyl)methacrylamide copolymers by immobilized lectin. Macromol. Chem. Phys. 198:1997;1165-1180.
103. Tersikh A.V., Le Doussal J.-M., Crameri R., Fisch I., Mach J.-P., Kajava A.V. "Peptabody": a new type of high avidity binding protein. Proc. Natl. Acad. Sci. USA. 94:1997;1663-1668.
104. Nemerow G.R., Houghten R.A., Moore M.D., Cooper N.R. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell. 56:1989;369-377.
105. Watry D., Hedrick J.A., Siervo S., Rhodes G., Lamberti J.J., Lambris J.D., Tsoukas C.D. Infection of human thymocytes by Epstein-Barr virus. J. Exp. Med. 173:1991;971-980.
106. Omelyanenko V., Kopečková P., Prakash R.K., Ebert C.D., Kopeček J. Biorecognition of HPMA copolymer-adriamycin conjugates by lymphocytes mediated by synthetic receptor binding epitopes. Pharm. Res. 16:1999;1010-1019.
107. Tang A., Wang C., Stewart R., Kopeček J. Self-assembled peptide monolayer displaying epitopes recognizable by human lymphoma cells, 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA. AAPS Pharm. Sci. 1:1999;S442.
108. Tang A., Wang C., Stewart R., Kopeček J. Self-assembled peptides exposing epitopes recognizable by human lymphoma cells. Bioconjugate Chem. 2000;. submitted.
109. Ulbrich K., Pechar M., Strohalm J., Šubr V. Polymeric carriers of drugs for site-specific therapy. Macromol. Symp. 118:1997;577-585.
110. Ulbrich K., Šubr V., Strohalm J., Plocová D., Jelínková M., Říhová B. Polymeric drugs based on conjugates of synthetic and natural macromolecules. I. Synthesis and physico-chemical characterization. J. Control. Release. 64:2000;63-79.
111. 2-targeted conjugates and combined therapy with immunomodulators. J. Control. Release. 64:2000;241-261.
112. Satchi R., Duncan R. PDEPT: polymer directed enzyme therapy. Proc. Int. Symp. Control. Release Bioact. Mater. 24:1997;773-774.
113. Satchi R., Conors T.A., Duncan R. PDEPT: in vivo pharmacokinetics and pharmacology. Proc. Int. Symp. Control. Release Bioact. Mater. 26:1999;126-127.
114. Senter P.D., Wallace P.M., Svensson H.P., Vrudhula V.M., Kerr D.E., Hellström I., Hellström K.E. Generation of cytotoxic agents by targeted enzymes. Bioconjugate Chem. 4:1993;3-9.
115. Niculescu-Duvaz I., Spooner R., Marais R., Springer C.J. Gene-directed enzyme prodrug therapy. Bioconjugate Chem. 9:1998;4-22.
116. Duncan R., Kopečková-Rejmanová P., Strohalm J., Hume I., Cable H.C., Pohl J., Lloyd J.B., Kopeček J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 1. Evaluation of daunomycin and puromycin conjugates in vitro. Br. J. Cancer. 55:1987;165-174.
117. Duncan R., Kopečková P., Strohalm J., Hume I.C., Lloyd J.B., Kopeček J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 2. Evaluation of daunomycin conjugates in vivo against l1210 leukaemia. Br. J. Cancer. 57:1988;147-156.
118. Duncan R., Hume I.C., Kopečková P., Ulbrich K., Strohalm J., Kopeček J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukaemia L1210 in vivo. J. Control. Rel. 10:1989;51-63.
119. Seymour L.W., Ulbrich K., Steyger P.S., Brereton M., Šubr V., Strohalm J., Duncan R. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer. 70:1994;636-641.
120. Minko T., Kopečková P., Pozharov V., Jensen K., Kopeček J. The influence of cytotoxicity of macromolecules and of VEFG gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumor. Pharm. Res. 17:2000;505-514.
121. Duncan R., Wasil M., Gianasi E., Keddle A., Evagorou E.G., Buckley R.G., Wilson G. Comparative evaluation of novel polymer platinates. II. Antitumor activity and biodistribution in vivo. Proc. Int. Symp. Control. Release Bioact. Mater. 24:1997;83-84.
122. N. Mongelli, E. Pesenti, A. Suarato, G. Biasoli, Polymer-bound paclitaxel derivatives, US Patent 5,362,831 (1994).
123. Mendichi R., Rizzo V., Gigli M., Razzano G., Angelucci F., Giacometti Schieroni A. Molar mass distribution of a polymer-drug conjugate containing the antitumor drug paclitaxel by size exclusion chromatography and universal calibration. J. Liq. Chrom. Release Technol. 21:1998;1295-1309.
124. Říhová B., Strohalm J., Plocová D., Šubr V., Šrogl J., Jelínková M., Šírová M., Ulbrich K. Cytotoxic and cytostatic effect of anti-Thy 1.2 targeted doxorubicin and cyclosporin A. J. Control. Release. 40:1996;303-319.
125. Jelínková M., Strohalm J., Plocová D., Šubr V., Šťastný M., Ulbrich K., Říhová B. Targeting of human and mouse T-lymphocytes by monoclonal antibody-HPMA copolymer-doxorubicin conjugates directed against different T-cell surface antigens. J. Control. Release. 52:1998;253-270.
126. Šťastný M., Říhová B., Strohalm J., Ulbrich K. Comparison of the binding kinetics of antibody targeted N-(2-hydroxypropyl)methacrylamide (HPMA)-bound doxorubicin in vitro and in vivo. J. Control. Release. 42:1996;229-236.
127. 6 conjugates and a preliminary study of their photodynamic effect on mouse splenocytes in vitro. Makromol. Chem. 191:1990;839-856.
128. 6, targeted by galactosamine or anti-Thy-1.2 antibodies, respectively. J. Control. Release. 25:1993;71-87.
129. Říhová B., Jegorov A., Strohalm J., Matha V., Rossmann P., Fornůsek L., Ulbrich K. Antibody-targeted cyclosporin A. J. Control. Release. 19:1992;25-40.
130. Šťastný M., Ulbrich K., Strohalm J., Rossmann P., Říhová B. Abnormal differentiation of thymocytes induced by free cyclosporine is avoided when cyclosporine bound to N-(2-hydroxypropyl)methacrylamide copolymer is used. Transplantation. 63:1997;1818-1827.
131. Rossmann P., Říhová B., Strohalm J., Ulbrich K. Morphology of rat kidney and thymus after native and antibody-coupled cyclosporin A application (reduced toxicity of targeted drug). Folia Microbiol. 42:1997;277-287.
132. 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. J. Drug Targeting. 3:1996;385-390.
133. Flanagan P.A., Duncan R., Šubr V., Ulbrich K., Kopečková P., Kopeček J. Evaluation of protein-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug-carriers. 2. Body distribution of conjugates containing transferrin, antitransferrin receptor antibody or anti-Thy 1.2 antibody and effectiveness of transferrin-containing daunomycin conjugates against mouse L1210 leukaemia in vivo. J. Control. Release. 18:1992;25-38.
134. O'Hare K.B., Duncan R., Strohalm J., Ulbrich K., Kopečková P. Polymeric drug carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma. J. Drug Targeting. 1:1993;217-229.
135. Henderson B.W., Dougherty T.J. How does photodynamic therapy work? Photochem. Photobiol. 55:1992;145-157.
136. Spikes J.D. Photosensitization. Smith K.C. The Science of Photobiology. 2nd ed. 1989;79-110 Plenum Press, New York.
137. Gu Z.-W., Spikes J.D., Kopečková P., Kopeček J. Synthesis and photoproperties of a substituted zinc (II) phthalocyanine-N-(2-hydroxypropyl)methacrylamide copolymer conjugate. Collection Czechoslov. Chem. Commun. 58:1993;2321-2336.
138. J. Kopeček, N.L. Krinick, Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light, US Patent 5,258,453 (1993).
139. Krinick N.L., Sun Y., Joyner D., Spikes J.D., Straight R.C., Kopeček J. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomat. Sci. Polym. Ed. 5:1994;303-324.
140. Peterson C.M., Lu J.M., Sun Y., Peterson C.A., Shiah J.-G., Straight R.C., Kopeček J. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res. 56:1996;3980-3985.
141. 6 monoethylene diamine induced photodynamic therapy in human epithelial ovarian carcinoma in vivo. Int. J. Oncol. 15:1999;5-16.
142. 6 conjugates. J. Phys. Chem. B. 101:1997;6803-6809.
143. 6 conjugates. Drug Delivery. 5:1998;119-126.
144. 6 and adriamycin conjugates in combination treatments. Clin. Cancer Res. 6:2000;1008-1015.
145. 6/adriamycin conjugates in cancer therapy. Proc. Int. Symp. Contr. Release Bioact. Mater. 26:1999;1058-1059.
146. German U.A. P-glycoprotein: a mediator of multidrug resistance in tumour cells. Eur. J. Cancer. 32A:1996;927-944.
147. Loe D.W., Decley R.G., Cole S.P.C. Biology of the multidrug resistance associated protein, MRP. Eur. J. Cancer. 32A:1996;945-957.
148. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54:1994;4313-4320.
149. Ryser H.J.-P., Shen W.-C. Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc. Natl. Acad. Sci. USA. 75:1978;3867-3870.
150. Ohkawa K., Hatano T., Yamada K., Joh K., Takada K., Tsukada Y., Matsuda M. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res. 53:1993;4238-4242.
151. Šťastný M., Strohalm J., Plocová D., Ulbrich K., Říhová B. A possibility to overcome P-glycoprotein (PGP)-mediated multidrug resistance by antibody-targeted drugs conjugated to N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier. Eur. J. Cancer. 35:1999;459-466.
152. S.R. Wedge, Mechanism of action of polymeric anthracyclines: potential to overcome multidrug resistance, Ph.D. Dissertation, Keele University (1990).
153. Alakhov V.Y., Moskaleva E.Y., Batrakova E.V., Kabanov A.V. Hypersensitization of multidrug resistant human ovarian carcinoma cells by Pluronic P85 block copolymer. Bioconjugate Chem. 7:1996;209-216.
154. Warren L., Jardillier J.-C., Malarska A., Akeli M.-G. Increased accumulation of drugs in multidrug resistant cells induced by liposomes. Cancer Res. 52:1992;3241-3245.
155. Cuvier C., Roblot-Treupel L., Millot J.M., Lizard G., Chevillard S., Manfait M., Couvreur P., Poupon M.F. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem. Pharmacol. 44:1992;509-517.
156. Omelyanenko V., Kopečková P., Gentry C., Kopeček J. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J. Control. Release. 53:1998;25-37.
157. Dvorak H.F., Nagy J.A., Dvorak J.T., Dvorak A.M. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133:1988;95-109.
158. Vasey P.A., Twelves C., Kaye S.B., Wilson P., Morrison R., Duncan R., Thomson A., Murray L., Hilditch T.E., Murray T., Burtles S., Frigerio E., Fraier D., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer-doxorubicin): first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. 5:1999;83-94.
159. Thompson A.H., Vasey P.A., Murray L.S., Cassidy J., Fraier D., Frigerio E., Twelves C. Population pharmacokinetics in phase I drug development: a phase I study of PK1 in patients with solid tumors. Br. J. Cancer. 81:1999;99-107.
160. Julyan P.J., Seymour L.W., Ferry D.R., Daryani S., Boivin C.M., Doran J., David M., Anderson D., Christodolou C., Young A.M., Hesselwood S., Kerr D.J. Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine. J. Control. Release. 57:1999;281-290.
161. Ciaolfa V.R, Zamai M., Fiorino A., Frigerio E., Pellizzoni C., d'Argy R., Ghiglieri A., Castelli M.G., Farao M., Pesenti E., Gigli M., Angelucci F., Suarato A. Polymer-bound camptothecin: initial biodistribution and antitumor activity studies. J. Control. Release. 65:2000;105-119.
162. V.R. Ciaolfa, E. Frigerio, M.G. Castelli, I. Poggesi, A. Fiorino, A. Marsiglio, P.P. Lovisolo, M. Farao, F. Sola, E. Pesenti, M. Zamai, F. Angelucci, A. Suarato, HPMA-based tumor delivery: pharmacokinetics and antitumor activity of the first MAG-phe-leu-gly-CPT soluble derivative, American Association of Cancer Research Meeting, New Orleans, LA, Abstract 2923 (1998).
163. Gewirtz A.M., Sokol D.L., Ratajczak M.Z. Nucleic acid therapeutics: state of the art and future prospects. Blood. 92:1998;712-736.
164. Wagner E. Application of membrane-active peptides for nonviral gene delivery. Drug Delivery Rev. 38:1999;279-289.
165. Wang L., Kristensen J., Ruffner D.E. Delivery of antisense oligonucleotides using HPMA polymer: synthesis of a thiol polymer and its conjugation to water-soluble molecules. Bioconjugate Chem. 9:1998;749-757.
166. Jensen K., Kopečková P., Kopeček J. Studying the fate of antisense oligonucleotide/polymer conjugates targeted to HepG2 cells, 14th Annual Meeting of the American Association of Pharmaceutical Scientists, New Orleans, LA. AAPS Pharm. Sci. 1:1999;S624.
167. Toncheva V., Wolfert M.A., Dash P.R., Oupický D., Ulbrich K., Seymour L.W., Schacht E.H. Novel vectors for gene delivery formed by self-assembly of DNA with poly(L-lysine) grafted with hydrophilic polymers. Biochim. Biophys. Acta. 1380:1998;354-368.
168. Oupický D., Koňák Č., Ulbrich K. Preparation of DNA complexes with diblock copolymers of poly[N-(2-hydroxypropyl)methacrylamide] and polycations. Mat. Sci. Eng. C7:1999;59-65.
169. Oupický D., Koňák Č., Ulbrich K. DNA complexes with block and graft copolymers of N-(2-hydroxypropyl)methacrylamide and 2-(trimethylammonio)ethyl methacrylate. J. Biomat. Sci. Polym. Ed. 10:1999;573-590.
170. Koňák Č., Mrkvičková L., Nazarova O., Ulbrich K., Seymour L.W. Formation of DNA complexes with diblock copolymers of poly[N-(2-hydroxypropyl)methacrylamide] and polycations. Supramolecular Sci. 5:1998;67-74.
171. Kuida K., Haydar T.F., Kuan C.-Y., Gu Y., Taya C., Karasuyama H., Su M.S.-S., Rakic P., Flavell R.A. Reduced apoptosis and cytochrome c - mediated caspase activation in mice lacking caspase 9. Cell. 94:1998;325-337.
172. Heiden M.G.V., Chandel N.S., Williamson E.K., Schumacker P.T., Thomson C.B. Bcl-xl regulates the membrane potential and volume homeostasis of mitochondria. Cell. 91:1997;627-637.
173. Reed J.C. Cytochrome c: can't live with it - can't live without it. Cell. 91:1997;559-562.
174. Liu X., Kim C.N., Yang J., Jemmerson R., Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 86:1996;147-157.
175. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., Wang X. Cytochrome c and dATP-dependent formation of Apaf1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:1997;479-489.
176. Kim K.H., Hirano T., Ohashi S. Anticancer polymeric prodrugs, targetable. Salomone J.C. Polymer Materials Encyclopedia. 1996;272-285 CRC Press, Boca Raton, FL.
177. Khan J., Bittner M.L., Chen Y., Meltzer P.S., Trent J.M. DNA microarray technology: the anticipated impact on the study of human disease. Biochim. Biophys. Acta. 1423:1999;M17-M28.
178. Schummer M., Ng W.V., Bumgarner R.E., Nelson P.S., Schummer B., Bednarski D.W., Hassell L., Baldwin R.L., Karlan B.Y., Hood L. Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinoma. Gene. 238:1999;375-385.